The middle T antigen of murine Polyomavirus (PymT) rapidly transforms endothelial cells leading to vascular malformations reminiscent of endothelial tumors or hemangiomas. Flk-1, a receptor tyrosine kinase which is activated upon binding of its ligand VEGF, is predominantly expressed in endothelial cells and essential for the formation of blood vessels since absence of Flk-1 prevents the development of mature endothelial cells in mice and in ES-cell dierentiation experiments. To investigate the role of Flk-1 in PymT-induced vascular tumor formation, we studied the expression of Flk-1 and VEGF in PymT-transformed endothelial cells (Endothelioma cells, END. cells). The receptor and its ligand were both expressed in END. cells suggesting that a VEGF/ Flk-1 autocrine loop might be causally involved in the formation of vascular tumors. To test this hypothesis, ES cells lacking Flk-1 were generated and the transforming potential of PymT was analysed after in vitro dierentiation. Flk-17/7 END. cell lines were established which are morphologically identical to¯k-1+/+ END. cells and which express several markers characteristic for endothelial cells. This result suggests that PymT functionally replaces the requirement of Flk-1 in expansion and/or survival of endothelial progenitor cells. Therefore,¯k-17/7 END. cells provide a powerful tool to dissect the downstream signaling pathways of Flk-1.
Introduction
The murine Polyomavirus middle T antigen (PymT) is known to speci®cally transform endothelial cells in vivo. This transformation process occurs with rapid kinetics, leading to the formation of hemorrhagic cystic tumors in embryonic and neonatal mice (for review see Pepper et al., 1997) . These tumors are reminiscent of human vascular tumors since they are endothelial speci®c and organ nonspeci®c. Furthermore, these tumor-bearing mice develop symptoms of the Kasabach-Merritt syndrome, i.e. anemia and thrombocytopenia (Dubois-Stringfellow et al., 1994) . Permanent endothelioma (END.) cell lines could be established from vascular tumors which exhibit altered proteolytic activity due to increased expression of urokinase-type plasminogen activator (uPA) (Montesano et al., 1990) .
Their tumorigenicity is highly dependent on the proteolytic status of both, the tumor cells and the host .
The oncogenic properties of PymT are thought to be a consequence of its interaction with several cellular proteins which are key components of signal transduction cascades leading to cellular proliferation. These proteins include the adapter molecule Src-homology/ collagen (Shc), phospholipase Cg (PLCg), the 85 kD regulatory subunit of phosphatidyl inositol 3-kinase (PI 3-kinase), the regulatory and catalytic subunits of the serine/threonine phosphatase 2A, 14-3-3 proteins and at least three members of the Src tyrosine kinase family: Src, Fyn and Yes (DiMaio et al., 1998; Kiefer et al., 1994a) . Although studies by Kiefer et al. (1994b) have established a critical role for the PymT-Yes kinase complex in the tumor-initiating action of PymT, the molecular mechanisms responsible for the tissue speci®city of the PymT transforming activity have not been identi®ed.
Establishing a blood vessel system is a central step during embryogenesis. In fact, the vasculature is functioning before any other organ. Therefore, dierentiation and proliferation of endothelial cells need to be tightly regulated. A variety of angiogenic growth factors and their endothelial receptors has been implicated in the complex multistep processes of vasculogenesis (dierentiation of an endothelial progenitor, the angioblast, into an endothelial cell) and angiogenesis (formation of capillaries from pre-existing blood vessels) (Hanahan, 1997; Risau, 1997; Wagner and Risau, 1994) . Among these molecules the members of the vascular endothelial growth factor family (consisting of VEGF, VEGF-B, VEGF-C, VEGF-D and PlGF) seem to have the most important biological function. Members of the ®broblast growth factor family (acidic and basic FGF) show angiogenic activity at least in dierent angiogenesis assays.
VEGF (VEGF-A) is a disulphide-linked 46 kD glycoprotein related to platelet-derived growth factor (PDGF). Presently, at least four VEGF splice variants are known, which dier in their secretion properties and their heparin binding anities. Despite its function as endothelial growth factor, VEGF is also a potent vascular permeability factor and therefore also termed VPF (vascular permeability factor). Currently, three dierent transmembrane receptor tyrosine kinases (RTKs) are known which are activated by the various VEGF family members. These receptors are Flt-1 (VEGFR-1), Flk-1/KDR (VEGFR-2) and Flt-4 (VEGFR-3). Based on their common structural feature which is the so-called`kinase-insert-domain', they belong to the family of the PDGF receptor. Members of this receptor family dier in their extracellular domain, since this domain of Flt-1, Flk-1 and Flt-4 is composed of seven immunoglobulin (Ig)-like loops, in contrast to only ®ve extracellular Ig-like loops found in the PDGF receptor (Korpelainen and Alitalo, 1998; Neufeld et al., 1999) . VEGF exerts its function through binding to Flt-1 and Flk-1, which are expressed predominantly on endothelial cells. Flt-1 and Flk-1 dier in their anity to VEGF and probably also in the signal transduction pathways activated upon ligand binding (Seetharam et al., 1995; Waltenberger et al., 1994) . Flt-1 also binds to PlGF and VEGF-B, whereas Flk-1 also interacts with VEGF-C and VEGF-D. The third member of the VEGF receptor family, Flt-4, seems to be speci®cally expressed on lymphatic vessels (Kaipainen et al., 1993 (Kaipainen et al., , 1995 and mainly activated by VEGF-C (Jeltsch et al., 1997; Joukov et al., 1996) .
The importance of VEGF and its receptors for proper blood vessel formation was demonstrated by targeted inactivation of the respective genes in the mouse. All these mutant mice show embryonic lethality although with dierent phenotypes. Mice heterozygous for either Flt-1 or Flk-1 develop normally and show no phenotype. In contrast, heterozygous VEGF mutant mice die before embryonic day 11 (E11) due to impaired vasculogenesis in yolk sac and embryo (Carmeliet et al., 1996; Ferrara et al., 1996) . Flt-17/7 mice die after E9.0 and show impaired vasculogenesis, dilated blood vessels and disorganized assembly of endothelial cells (Fong et al., 1995) . Mice lacking Flk-1 show the most dramatic phenotype. These mice die between E8.5 and E9.5 with failure of yolk sac blood island formation and vasculogenesis. Endothelial cell dierentiation was completely absent in¯k-17/7 embryos suggesting a critical role of Flk-1 in this process (Shalaby et al., 1995) . These ®ndings were supported by the use of¯k-17/7 ES cells which do not contribute to the vasculature of chimeric embryos and fail to differentiate into endothelial cells in vitro (Shalaby et al., 1997) . Here, we show that PymT is able to replace Flk-1 in the expansion and proliferation of endothelial cells in vitro since PymT-transformed endothelioma cells were formed in the absence of Flk-1.
Results

END. cells express Flk-1 and secrete its ligand VEGF
The protein tyrosine kinase expression pro®le of Polyoma middle T-transformed endothelial cells was characterized by a reverse transcriptase-polymerase chain reaction (RT ± PCR) strategy using degenerate primers derived from conserved regions of the tyrosine kinase domain (Wilks et al., 1989) . Sequencing of the subcloned PCR fragments revealed ± among others ± the expression of the receptor tyrosine kinases Tie-1, Flt-1 and Flk-1 which are preferentially expressed in endothelial cells. The expression of Flk-1 was con®rmed by Northern blot analysis ( Figure 1a and Sabapathy et al. (1997) ) and by the presence of an enzymatically active kinase. Lysates from END. cells (unstimulated or VEGF stimulated) were immunoprecipitated (Millauer et al., 1993) and phosphorylated Flk-1 together with additional tyrosine-phosphorylated proteins were detected after in vitro kinase reaction (Figure 1b) , indicating that Flk-1 is expressed as an enzymatically active receptor tyrosine kinase. This result was con®rmed by in vitro kinase assays using radioactively labeled g-32 P-ATP (data not shown). We next investigated whether also the Flk-1 ligand VEGF is expressed by END. cells. All END. cell lines tested by Northern blot analysis (Figure 1c) showed expression of VEGF mRNA. RT ± PCR analysis revealed that at least three VEGF splice variants are expressed by endothelioma cells (Figure 1d ). To investigate whether END. cells are also capable of producing and secreting VEGF, conditioned medium produced by two dierent END. cell lines was puri®ed by ion exchange chromatography and the eluate tested by Western blot analysis. Both secreted VEGF isoforms (VEGF-120 and VEGF-164) could be detected in the conditioned medium (Figure 1e ), indicating that END. cells co-express Flk-1 and its ligand VEGF, thereby potentially generating an autocrine loop. Vegf was found to be co-localized to sites of¯k-1 expression as shown in (e) using a mouse vegf antisense probe. A vegf sense probe did not show any speci®c staining (d)
PymT-induced vascular lesions coexpress Flk-1 and VEGF We next asked whether this co-expression of Flk-1 and VEGF observed in vitro can also be detected in vivo. Vascular lesions were induced in¯k-1+/7 mice by PymT retroviral injections. These mice carry a lacZ gene fused in frame to the ®rst ATG of Flk-1 (Shalaby et al., 1995) and can therefore be used as a reporter strain for Flk-1 expression. LacZ-positive cells lining the tumor mass of the vascular lesions were detected (Figure 2a, b) . Immunocytochemical analysis of the X-gal stained sections using an antibody directed against von-Willebrand-factor identi®ed the lacZ-positive cells as endothelial cells (Figure 2c ). Furthermore, in situ hybridization studies on sections of PymT-induced vascular tumors using VEGF and k-1 probes revealed that VEGF expression colocalized to sites that are also positive for Flk-1 expression (Figure 2d ± f), indicating that a VEGF/Flk-1 autocrine loop may also exist in vivo consistent with the biochemical data.
Generation and analysis of¯k-17/7 CCE ES cell clones
To experimentally test whether a VEGF/Flk-1 autocrine loop might be causally involved in the formation of PymT-induced vascular lesions, an ES cell dierentiation system was employed. This method allows to recapitulate in vivo dierentiation steps under controlled in vitro conditions (Keller, 1995) . CCE ES cell clones lacking Flk-1 were generated as shown in Figure 3a . G418-resistant ES cell clones were analysed by PCR for homologous recombination or Cre-mediated recombination and the PCR results were con®rmed by Southern blot analysis using a¯k-1 genomic probe ( Figure 3b ). Two¯k-17/7 ES cell clones (180.4 and 180.5) were chosen for further analysis.
The¯k-17/7 ES cell clones were tested for their dierentiation capacity in vivo by injecting them into syngeneic mice to induce teratocarcinoma formation. Flk-17/7 ES cell clones behaved indistinguishably from wild type or¯k-1+/7 ES cells in terms of tumor frequency, tumor size and types of dierentiated tissues (data not shown).
Flk-1 expression was analysed by FACScan analysis after in vitro dierentiation of¯k-1+/7 and¯k-17/7 ES cells into embryoid bodies after 4, 6 and 9 days of ES cell dierentiation (Figure 4 ). Flk-17/7 ES cells are negative for Flk-1 expression, in contrast to¯k-1+/7 ES cells which served as a positive control (Figure 4a ). In addition, the expression of marker genes for the endothelial and hematopoietic lineages, such as CD31 (PECAM-1) and CD117 (c-kit), was studied to characterize the extent of dierentiation. Both¯k-1+/7 and k-17/7 ES cells expressed the markers CD31 and CD117 throughout the dierentiation experiment. The relative numbers of CD31-and CD117-positive cells were comparable for both ES cell types. Only after 9 days of ES cell dierentiation the relative number of CD31-positive cells derived from k-17/7 ES cells seemed to be reduced in comparison to the control (Figure 4b ).
PymT transformation of in vitro dierentiated k-17/7 ES cells Flk-17/7 ES cells were infected after 11 days of in vitro dierentiation with a retrovirus carrying the PymT oncogene and a puromycin resistance gene (pBABE-puro/PymT). Infection of¯k-1+/7 ES cells after in vitro dierentiation served as a positive control and the empty retroviral vector (pBABE-puro) as a negative control. Approximately 2 weeks after the infection with pBABE-puro/PymT the development of puromycin-resistant cells was observed which showed the characteristic spindle-shaped morphology of END. cells (Figure 6a ). These cells developed from¯k-17/7 ES cells as well as from¯k-1+/7 ES cells, whereas the development of spindle-shaped cells was not observed in the negative control. To establish clonal cell lines individual cell foci were picked and expanded under selection. Two independent lines carrying a single PymT integration and one mixed clone carrying two dierent PymT integration sites as con®rmed by Figure 3 Generation of¯k-17/7 CCE ES cell clones. (a) Schematic representation of the¯k-1 genomic locus depicting the promoter region, exon 1 and a part of the ®rst intron. A targeting vector was constructed to introduce loxP sites¯anking exon 1 by homologous recombination, allowing Cre/loxP mediated deletion of the promoter region along with exon 1. Flk-17/7 CCE ES cell clones were generated by a total of four electroporation rounds: a homologous recombination step was followed by a Cre/ loxP-mediated recombination step leading to a null allele. The second null allele was generated in the same way. (b) Southern blot analysis of ES cell clones after the electroporation steps using a¯k-1 genomic probe depicted in (a). The genomic DNA was digested with SpeI, cleaving at the 5' loxP site due to the diagnostic SpeI restriction site introduced by the homologous recombination step. Cre/loxP-mediated recombination causes loss of the diagnostic site resulting in a DNA fragment slightly smaller than the wild type fragment due to the deletion of the promoter/ exon 1 genomic region. One¯k-1+/7 (176.19) and twō k-17/7 ES cell clones (180.4 and 180.5) were used for subsequent analysis Southern blot analysis (data not shown) were established ( Table 1) .
The permanent cell lines (esEND.f1, esEND.f2 and esEND.f3) were further characterized to prove that they are indeed transformed endothelial cells. Western blot analysis revealed that Flk-1 protein was absent in these cells (Figure 5a ). Lack of Flk-1 immunoreactivity con®rmed the absence of Flk-1 expression consistent with the FACScan result. Furthermore, the Polyoma middle T antigen was expressed in the Flk-1-de®cient cell lines at the protein level (Figure 5b) . Next, expression studies for the endothelial marker genes, k-1 and tie-1 were performed at the mRNA level by Northern blot analysis (Figure 5c ). Whereas Flk-1 expression was clearly absent in¯k-17/7 cells, expression of the endothelial marker gene tie-1 was found in¯k-17/7 and the¯k-1+/+ control END. cells (eEND.2). Expression of two additional endothelial markers, PECAM-1 (CD31; Xie and Muller, 1993) and VE-Cadherin (CD144; Lampugnani et al., 1992), Figure 4 Marker analysis of¯k-1+/7 and¯k-17/7 ES cells after in vitro dierentiation. (a ± c) A¯k-1+/7 (176.19) and ā k-17/7 (180.4) ES cell clone were dierentiated in vitro into embryoid bodies. The embryoid bodies were harvested and disaggregated after 4, 6 and 9 days of dierentiation and analysed by FACScan for the expression of dierent marker genes (shown are the results for Flk-1, CD31/PECAM-1 and CD117/C-Kit). No striking dierence in the behaviour of the two dierent ES cell clones was detected, despite lacking Flk-1 expression in the case of the¯k-17/7 ES cell clone (a) Figure 5 Biochemical characterization of END. cells derived from¯k-17/7 ES cells. (a ± b) The three established cell lines (esEND.f1, esEND.f2 and esEND.f3) were analysed by Western blot for expression of Flk-1 (a) or PymT (b). Flk-1 expression was absent in the three¯k-17/7 cell lines like in the negative control Fib.mT (®broblastic cell line transformed with PymT). Flk-1 expression could be detected in eEND.2 cells which served as positive control. END.. cells were either unstimulated (7) or stimulated with FCS (+) before cell lyses (a). All cells carrying pBABE-puro/PymT (based on Southern blot analysis, data not shown), unlike untransformed 3T3 cells, were found to express PymT (b). (c) Northern blot analysis revealed absence of¯k-1 mRNA in all¯k-17/7 cell lines, whereas¯k-1 mRNA could be detected in¯k-1+/+ END. cells (eEND.2, tEND.1 and pEND.t38). In contrast, the endothelial-speci®c marker tie-1, known to be present in endothelioma cells, was found to be expressed in all three endothelioma-like cell lines lacking Flk-1. No expression of tie-1 could be detected in Fib.mT cells, which served as a negative control was investigated by immuno¯uorescence (Figure 6c ). PECAM-1 and VE-Cadherin are not expressed by PymT transformed ®broblasts (negative control), but are found to be expressed by¯k-1+/+ END. cells (eEND.2, positive control). All three¯k-17/7 END. cell lines showed expression of both endothelial marker genes consistent with the ®nding of tie-1 expression in these cell lines.
The¯k-17/7 END. cells were also analysed for their capacity to induce vascular tumors (secondary hemangiomas) upon injection into syngeneic mice. Mice injected with esEND.f cells developed tumors with the same frequency and kinetics as mice injected with¯k-1+/+ END. cells (Table 1 ). The histological analysis of the tumors induced by the¯k-17/7 END. cells revealed the typical cavernous and blood-®lled morphology of END. cell induced tumors (Figure 6b ).
Taken together, the biochemical and the in vivo data suggest that END. cells were formed by transforming dierentiated¯k-17/7 ES cells with PymT, indicating In addition to the expression of marker genes of endothelial cells (Tie-1, PECAM-1 and VE-Cadherin), all¯k-17/7 END. cell lines induced the formation of secondary hemangiomas upon injection into syngeneic mice. Tumor frequency and kinetics was not signi®cantly dierent between eEND.2 and the esEND.f lines. In contrast, Fib.mT cells (PymT-transformed ®broblastic cells) did not induce vascular lesions in mice that PymT can replace the requirement of Flk-1 in endothelial cell proliferation and/or survival.
Discussion
This study aimed to identify molecular events which are responsible for the tissue-speci®c action of the Polyoma middle T oncogene resulting in the formation of vascular tumors. The speci®c role of Flk-1 in this process was investigated based on the central function of Flk-1 for endothelial cell formation.
Both Flk-1 and its ligand VEGF were found to be expressed by END. cells suggesting that a VEGF/Flk-1 autocrine loop might be causally involved in the formation of the PymT-induced vascular lesions. Transforming oncogenes promote cell growth in vitro in a factor-independent way, resulting in cell-cycle progression even under reduced serum conditions, a phenomenon that holds true also in the case of PymTtransformed endothelioma cells. Thus, growth factor/ growth factor receptor autocrine loops are thought to be important in the pathogenesis of a variety of cancers, such as brain tumors, mammary carcinomas and melanomas (reviewed in Jones and Kane, 1996; Sporn and Roberts, 1985) . VEGF, a member of the PDGF family of growth factors, is generally believed to act in a paracrine manner to stimulate endothelial cell growth. It is secreted by stromal cells and its receptors Flt-1 and Flk-1 are expressed predominantly on endothelial cells. This mode of action establishes a chemotactic gradient towards the endothelial cell will grow and migrate which ®nally leads to the formation of a capillary network (for review see Risau, 1997) . In contrast to the paracrine mode of action, there is evidence that angiogenic factors can also act in an autocrine manner, mainly in the context of angioproliferative diseases, including Kaposi's sarcoma or angiosarcoma (Hashimoto et al., 1995; Masood et al., 1997) . Furthermore, it has been shown that overexpression of bFGF (FGF-2) in endothelial cells resulted in a transformed morphology of these cells in vitro and formation of hemangioma-like lesions in vivo (Gualandris et al., 1996) , probably mediated through the upregulation of autocrine acting VEGF (Seghezzi et al., 1998) . Expression of bFGF and FGFR-1 has been found in PymT-transformed endothelial cells (data not shown), but PymT-mediated tumor induction experiments using mice lacking bFGF have clearly ruled out a critical function of bFGF in PymT-mediated vascular tumor formation (C Basilico, personal communication). VEGF itself has so far not been shown to act as an oncogene, instead activated oncogenes can induce or enhance the production of VEGF (Rak et al., 1995) .
To study the functional consequences of Flk-1 de®ciency on PymT-mediated endothelial cell transformation in vitro, END. cells from dierentiated ES cells lacking Flk-1 were generated which are morphologically and by marker gene expression indistinguishable from¯k-1+/+ END. cells suggesting that a VEGF/ Flk-1 autocrine loop is not essential for the PymT transformation process in vitro. When injected into syngeneic mice, END. cell-induced tumor formation was not impaired in the absence of Flk-1, indicating that Flk-1 is also not required for the proliferation of PymT-transformed endothelial cells in vivo.
The generation of END. cells in the absence of Flk-1 is an intriguing ®nding in light of the generally accepted concept that Flk-1 is essential for the formation of endothelial cells (Shalaby et al., 1995 (Shalaby et al., , 1997 . This result can best be explained by functional replacement of Flk-1 by PymT in the expansion of endothelial progenitor cells (Figure 7 ). PymT together with its associated cellular proteins is believed to closely resemble the transmembrane and cytoplasmic domains of an activated growth factor receptor bound to its interacting molecules, thereby delivering a constitutive mitogenic signal to the cell (Dilworth, 1995) . Endothelial cell progenitors devoid of the mitogenic signal which is normally provided by the Flk-1 tyrosine kinase fail to generate proliferating endothelial cells. However, it is not entirely clear at which stage of endothelial cell formation Flk-1 is essential. Data by Shalaby et al. (1995 Shalaby et al. ( , 1997 together with the report on the identi®cation of a cell population likely to represent the long-hypothesized hemangioblast (Choi et al., 1998) argue that Flk-1 is required for the commitment into the endothelial cell lineage at the hemangioblastic stage. In contrast, two more recent papers provide strong evidence for the fact that Flk-1 is not required for the commitment of an endothelial progenitor, but for its expansion after lineage commitment (Hatzopoulos et al., 1998; Schuh et al., 1999) . Schuh et al. (1999) were able to detect endothelial marker gene expression, such as tie-1,¯t-1 and pecam-1, after in vitro dierentiation of¯k-17/7 R1 ES cells, indicating that the dierentiation potential into endothelial progenitor cells is not aected in the (Keller, 1995) . In the absence of Flk-1, endothelial cell formation is drastically impaired in vitro (Shalaby et al., 1997) , probably due to a proliferation defect of the endothelial progenitor cells (angioblasts) (Schuh et al., 1999) . (b) Flk-17/7 ES cells which express the PymT antigen after in vitro dierentiation are capable of forming END. cells, indicating that PymT can functionally bypass the requirement of Flk-1 for the proliferation of the committed endothelial progenitor cells. Depicted in the box are the marker genes which are expressed by the¯k-17/7 END. cells absence of Flk-1. Rather, Flk-1-de®cient endothelial progenitor cells seem to be impaired in their expansion or survival potential, as indicated by the greatly reduced numbers of blast colonies derived from k-17/7 embryoid bodies in comparison to the control. Alternatively, PymT might rescue Flk-1 de®cient endothelial cells from senescence.
A dierent explanation would be that other receptor tyrosine kinases or downstream signaling molecules are upregulated in the absence of Flk-1 and thereby compensating for Flk-1 de®ciency. The most likely candidate would be Flt-1 which binds VEGF with even higher anity than Flk-1. Expression of Flt-1 and VEGF were detected in the¯k-17/7 cell lines (data not shown) raising the possibility that a VEGF/Flk-1 autocrine loop is replaced by a VEGF/Flt-1 loop. Although this possibility has not formally been ruled out, three lines of evidence argue against an involvement of Flt-1. First, Flt-1 was not upregulated at the protein level in the absence of Flk-1 in comparison to¯k-1+/+ END. cells, ruling out a simple compensatory mechanism. Second, although Flt-1 and Flk-1 bind VEGF with high anity, the biological responses mediated by activation of the two RTKs seem to be dierent. Whereas activtion of Flk-1 results in a mitogenic response, activation of Flt-1 does not induce proliferation (Seetharam et al., 1995; Waltenberger et al., 1994) , indicating that the signal transduction pathways downstream of Flt-1 and Flk-1 are not identical. Third, studies using genetically modi®ed mice provide even stronger evidence that the function of Flt-1 is clearly dierent from Flk-1 (Fong et al., 1995; Hiratsuka et al., 1998) .
The signi®cance of the in vitro rescue of Flk-1 function by PymT needs to be further addressed in vivo. However, the¯k-17/7 in vitro dierentiation system established in this study in combination with either well-characterized mutants of the polyoma middle T oncogene which are no longer able to bind and activate certain signal mediating molecules (Bronson et al., 1997; Glenn and Eckhart, 1995; Young et al., 1995) or with downstream eector molecules (Chang et al., 1997) represents a unique tool to genetically dissect the signal transduction pathways downstream of an activated Flk-1 receptor.
Materials and methods
Flk-1 targeting vector
Murine¯k-1 genomic clones (kindly provided by Dr G Breier) were isolated from a 129Sv strain library. A 3.3 kb k-1 genomic fragment containing 1.8 kb of the promoter region, the ®rst exon and 1.1 kb of the ®rst intron was subcloned into pBluescript SK7. Into the BamHI-site (located 1.8 kb upstream of the transcriptional start site) a 50 bp long oligonucleotide containing a loxP-and a diagnostic SpeI-site was cloned. 5' of the introduced loxPsite a 4.86 kb genomic fragment was fused to generate the long arm of the targeting vector. A tk-neo cassette¯anked by two loxP-sites (derived from pGH-1, kindly provided by Dr K Rajewsky) was cloned into the SmaI-site located within the ®rst intron, resulting in a construct containing three loxPsites oriented in the same direction. In order to reduce the frequency of randomly integrated targeting vectors, a diphtheria toxin-A cassette without polyA-signal was cloned into the SalI-site of pBluescript SK7. The targeting vector was linearized with a NotI restriction digest. A 1.4 kb XhoI ± NcoI genomic fragment located within the ®rst intron (but outside of the targeting vector) was used as a probe for Southern blot analysis of the targeted ES cell clones.
Generation of¯k-17/7 CCE ES clones
Flk-17/7 CCE ES cell clones were generated by a homologous recombination step followed by a Cre/loxPmediated recombination step resulting in a null allele (Gu et al., 1994; Sauer and Henderson, 1988) . This procedure was repeated for the second allele. For the homologous recombination event 8.0610
6 CCE cells (Robertson et al., 1986) were electroporated with 15 mg of the targeting vector linearized with NotI. G418-resistant clones were analysed by PCR and Southern blotting for the correct targeting event.
Cre/loxP-mediated recombination was achieved by electroporation of 8.0610
6 targeted CCE cells with 15 mg of the Cre expression vector pMC-Cre (not linearized). Gangcyclovirresistant clones were analysed by PCR and Southern blotting for the deletion event generating a null allele.
Tumorigenicity assay
The ability of the generated CCE ES cell clones to form teratocarcinomas was tested as described by Hilberg and Wagner (1992) .
Growth and in vitro dierentiation of CCE ES cell clones
CCE embryonic stem cells were maintained and in vitro dierentiated according to Keller et al. (1993) and Vittert et al. (1996) . Brie¯y, undierentiated CCE ES cells were maintained in the absence of feeders on gelatinized¯asks in Dulbecco's modi®ed Eagle medium (DMEM, high glucose) supplemented with 15% FCS, 1% penicillin-streptomycin, 1% glutamine, 1% non-essential amino acids, 10 74 M 2-mercaptoethanol and leukemia-inhibitory factor (LIF). For the dierentiation cultures, the CCE cells were dissociated by trypsinization and cultured in DMEM (high glucose) supplemented with 15% FCS, 1% penicillin-streptomycin, 1% glutamine, 1% non-essential amino acids, 0.0037% monothioglycerol and ascorbic acid (56 mg/ml) on bacterialgrade dishes. In some dierentiation experiments, the medium was further supplemented with erythropoietin (Epo, 2 U/ml), vascular endothelial growth factor (VEGF, 50 ng/ml), ®broblast growth factor 2 (FGF-2, 100 ng/ml) and interleukin 6 (IL-6, 10 ng/ml).
PymT-induced generation of END. cells in vitro
A cDNA encoding PymT was subcloned into the retroviral vector pBABE-puro (Morgenstern and Land, 1990 ). The retroviral construct or the negative control (empty pBABEpuro vector) were transfected into the virus producer cell line GP+E86 using lipofectamine following the manufacturer's instructions (GIBCO). The viral supernatant was harvested from puromycin-resistant producer cells 7 ± 10 days after transfection. CCE cell clones were disaggregated approximately 11 days after start of in vitro dierentiation using collagenase (2 mg/ml) and infected with either pBABE-puro or pBABE-puro/PymT. Two days after infection puromycin selection (2.5 mg/ml) was started. Cells showing typical END. cell morphology were visible 10 ± 20 days after infection.
Derivation and maintenance of END. cell lines END. cell lines were established and maintained essentially as described previously (Kiefer et al., 1994a) . In brief,`islands' containing cells with endothelioma-like morphology were picked using cloning cylinders and grown as individual cell populations in DMEM medium (high glucose) supplemented with 5% FCS, 1% penicillin-streptomycin, 1% glutamine, 1% non-essential amino acids and 10 74 M 2-mercaptoethanol. The established¯k-17/7 END. cell lines were termed esEND.f1, esEND.f2 and esEND.f3 (see Table 1 ).
The following END. cell lines used in this study have been either published elsewhere (Kiefer et al., 1994a; or not been described previously: eEND.2, bEND.3, bEND.4, tEND.1 (+/+END. cells); gEND.y17, tEND.y20 (yes7/7); mEND.s5 (src7/7); mEND.f11 (fyn7/7); mEND.t37, pEND.t38 (tPA7/7); mEND.u23, sEND.u24 (uPA7/7); luEND.u1 (uPA7/7 tPA+/7). Genotypes of the respective END. cell line are indicated in brackets.
Northern blot hybridization
RNA analysis was carried out by standard Northern techniques (Montesano et al., 1990) . Two to three mg of poly(A) + RNA were loaded per lane. GAPDH was used as an internal loading control. The cDNA probes were kindly provided by Dr D Dumont (¯k-1) and Dr U Deutsch (tie-1).
RT ± PCR analysis
Reverse transcription reactions were carried out according to instructions provided by the manufacturer (GIBCO Superscript Kit) using 250 ng of template poly(A) + RNA. PCR reactions were performed with primers for b2-tubulin (5'CAACGTCAAGACGGCCGTGTG-3' and 5'-GACA-GAGGCAAACTGAGCACC-3'; data not shown) and VEGF (5'-CACCAAAGCCAGCACATAGG-3' and 5'-CCGCCTCGGCTTGTCACATC-3'). An aliquot of the reverse-transcribed RNA was ampli®ed (VEGF: 948C for 60 s, 55 or 608C for 45 s and 728C for 90 s; b2-tubulin: 948C for 30 s, 568C for 30 s and 728C for 60 s) for 36 cycles. Final extension was achieved by 5 min incubation at 728C. The ampli®ed products were analysed on a 2.5% (w/v) agarose gel, and the identity con®rmed by subcloning and sequencing.
Immunoblotting and in vitro kinase assay
Detection of VEGF in the conditioned media recovered from the insulinoma and END. cell lines by immunoblotting was carried out as described in Christofori et al. (1995) . For the in vitro kinase assay cells were washed with ice-cold PBS and then lysed in lysis buer (100 mM Tris, 150 mM NaCl, 2 mM EDTA, 1% Nonidet P-40, pH 8.0 containing 1 mM phenylmethylsulfonyl¯uoride, 10 mg/ml leupeptin, 10 mg/ml chymostatin and 10 mg/ml pepstatin A as protease inhibitors) on ice. Cell debris was separated from the detergent-soluble fraction by centrifuging in a 48C microfuge at top speed for 5 min. Supernatants were transferred to fresh tubes and protein concentration was determined photometrically by Bradford assay (Bio-Rad) to adjust for equal protein amounts. Flk-1 protein complexes were immunoprecipitated at 48C on a rotating wheel using a rabbit polyclonal anti-Flk-1 antibody (CT128, kindly provided by Dr A Ullrich). After overnight incubation with the antibody protein G plus/protein A-agarose (Oncogene Research Products, Calbiochem) was added and incubation at 48C was continued for an additional 2 h. The beads were pelleted by gentle centrifugation and washed three times with lysis buer and once with 20 mM HEPES buer. Kinase reaction was carried in 20 ml of kinase assay buer (20 mM HEPES, 10 mM MgCl 2 , 10 mM MnCl 2 , 50 mM ATP, pH 8.0) for 10 min at 258C. The reaction was stopped by adding 10 ml 36SDS sample buer and boiling for 5 min. Protein samples were resolved on a SDS ± PAGE gel according to Laemmli (1970) and transferred onto a PVDF membrane (Millipore) using the semi-dry blotting technique.
Membranes were blocked and incubated with an antibody recognizing phosphorylated tyrosine residues (1 : 10 000 dilution of clone 4G10, UBI). Reactive protein bands were visualized using ECL detection kit (Amersham) according to manufacturer's instructions. Identity of phosphorylated proteins was con®rmed by incubation with a monoclonal anti-Flk-1 antibody (clone 88D4B9, kindly provided by Dr BuÈ hring) after stripping the membrane. Flk-1 and PymT immunoblots from whole cell lysates were carried out in the same way using CT28 (1 : 1000 dilution) to detect Flk-1 and the monoclonal antibody F4 (1 : 40 dilution, kindly provided by Dr E Ogris) to detect PymT.
FACScan analysis
Embryoid bodies grown in liquid culture were harvested and transferred to Hanks' buered saline (HBS) containing 5 mM EDTA and 25 mM HEPES (pH 7.4) and resuspended as single cells by repeated pipetting steps. Cells were washed with phosphate buered saline (PBS) containing 2% fetal calf serum (FCS) and 1 mM EDTA. The cells were stained with the appropriate antibodies (anti-CD31, PE-labeled and anti-CD117, APC-labeled; both purchased from Pharmingen; rat anti-Flk-1, kindly provided by Dr Nishikawa) for 30 min and washed twice with PBS/2% FCS. Cells stained with the Flk-1 antibody were incubated with a goat anti-rat antibody (PElabeled, DIANOVA) for an additional 15 min and washed again. FACScan analysis was carried out on FACS Vantage (Becton Dickinson).
Immunostaining and¯uorescence microscopy
Cells were washed twice with DMEM containing 25 mM HEPES and 5% FCS (washing buer), and then incubated for 20 min with the primary antibody either raised against CD31/PECAM-1 (1 : 50 dilution of hybridoma supernatant from clone MEC13.3, (Vecchi et al., 1994) ) or against CD144/VE-Cadherin (10 mg/ml, Pharmingen, (Gotsch et al., 1997) ). Following the primary antibody incubation the cells were washed twice with washing buer and then stained with the secondary antibody (1 : 200 dilution of Cy3 anti-rat, purchased from DIANOVA) for another 20 min. Cells were washed with washing buer and PBS followed by 10 min ®xation with 1% paraformaldehyde in PBS. Nuclei were stained with 4,6-diamidino-2-phenylindole (DAPI). The cells were visualized on a Zeiss Axiophot microscope and image acquisition was carried out using IPLab spectrum IO software (Signal Analytics).
Immunohistochemistry, immunocytochemistry and in situ hybridization
For¯k-1/lacZ reporter assay tissue specimens were explanted, dissected and stained with X-gal as described previously (Urbanek et al., 1994) and embedded in paran. Sections were counterstained with eosin. Adjacent sections were used for immunocytochemical detection of von-Wille-brand-factor (vWF) expression to identify endothelial cells (anti-vWF antibody, Dako). Secondary hemangiomas and teratocarcinomas were ®xed in 4% paraformaldehyde and embedded in paran. Sections were stained with hematoxy-lin-eosin. In situ hybridization was performed as described by WizigmannVoos et al. (1995) .
Tumor induction by injection of END. cells into adult mice
For the induction of secondary hemangiomas, endothelioma cells (or PymT transformed ®broblasts as negative control) were trypsinized, washed with PBS and resuspended as singlecell suspension at a ®nal concentration of 2.0610 7 cells/ml in PBS. Five-week-old, male syngeneic 129/Sv mice were injected either intraperitoneally or subcutaneously with 0.1 ml of the cell suspension. Mice were sacri®ced after signs of tumor formation, the tumors explanted and processed for histological analysis.
